Zymeworks Inc. is a global biotechnology company focused on the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, primarily targeting difficult-to-treat cancers, autoimmune disorders, and inflammatory diseases. The company's scientific foundation rests on its proprietary protein engineering platforms, notably the Azymetric multispecific antibody platform, the ZymeLink antibody-drug conjugate (ADC) platform, and the EFECT platform for modulating immune system responses.
Zymeworks operates a hybrid business model that balances proprietary internal research and development with a royalty-driven asset aggregation strategy. Its lead partnered asset, Ziihera (zanidatamab-hrii), is a HER2-targeted bispecific antibody that has received regulatory approvals for biliary tract cancer and is being advanced globally through strategic collaborations with Jazz Pharmaceuticals and BeOne Medicines. The company's wholly-owned clinical pipeline includes novel ADCs and multispecific antibodies such as ZW191, ZW251, and ZW220, which target various solid tumors.
Revenue is entirely generated through its strategic partnerships and out-licensing agreements rather than direct commercial product sales. The company earns upfront payments, research and development funding, clinical and regulatory milestone payments, and tiered royalties on commercial sales from major pharmaceutical partners, including Jazz Pharmaceuticals, Johnson & Johnson, GlaxoSmithKline, and Daiichi Sankyo. In 2025, Zymeworks reported $106 million in revenue, driven predominantly by milestone achievements and option exercises across its collaboration portfolio. Geographically, while the company is incorporated in Delaware with corporate operations in the United States, its primary research and development facilities are located in Vancouver, British Columbia. Zymeworks competes in the highly intensive oncology and immunology spaces, leveraging its specialized protein engineering capabilities and non-dilutive royalty financing to sustain its clinical pipeline.
